The University of Chicago Header Logo

Connection

Seiko Diane Yamada to Female

Back to Details
This is a "connection" page, showing publications Seiko Diane Yamada has written about Female.
Seiko Diane Yamada
Connection Strength
0.458
Female
  1. Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome? Gynecol Oncol. 2019 07; 154(1):177-182.
    View in: PubMed
    Score: 0.034
  2. A prospective study evaluating diffusion weighted magnetic resonance imaging (DW-MRI) in the detection of peritoneal carcinomatosis in suspected gynecologic malignancies. Gynecol Oncol. 2016 07; 142(1):169-175.
    View in: PubMed
    Score: 0.027
  3. Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol. 2015 Jun; 137(3):485-9.
    View in: PubMed
    Score: 0.025
  4. Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure. Gynecol Oncol. 2012 Nov; 127(2):316-20.
    View in: PubMed
    Score: 0.021
  5. Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer. Gynecol Oncol. 2008 Dec; 111(3):537-9.
    View in: PubMed
    Score: 0.016
  6. PDGFR-alpha as a potential therapeutic target in uterine sarcomas. Gynecol Oncol. 2007 Mar; 104(3):524-8.
    View in: PubMed
    Score: 0.014
  7. The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res. 2006 Feb 15; 66(4):2264-70.
    View in: PubMed
    Score: 0.014
  8. Conservative management of chylous ascites after removal of a symptomatic growing retroperitoneal teratoma. Gynecol Oncol. 2006 Mar; 100(3):608-11.
    View in: PubMed
    Score: 0.013
  9. Stage IIIC small cell carcinoma of the ovary: survival with conservative surgery and chemotherapy. Obstet Gynecol. 2004 May; 103(5 Pt 2):1120-3.
    View in: PubMed
    Score: 0.012
  10. Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res. 2002 Nov 15; 62(22):6717-23.
    View in: PubMed
    Score: 0.011
  11. Utilization of an Electronic Patient-Reported Outcome Platform to Evaluate the Psychosocial and Quality-of-Life Experience Among a Community Sample of Ovarian Cancer Survivors. JCO Clin Cancer Inform. 2022 08; 6:e2200035.
    View in: PubMed
    Score: 0.011
  12. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019 05; 569(7758):723-728.
    View in: PubMed
    Score: 0.008
  13. Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer. Cell. 2018 09 20; 175(1):159-170.e16.
    View in: PubMed
    Score: 0.008
  14. Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. Cell Metab. 2019 01 08; 29(1):141-155.e9.
    View in: PubMed
    Score: 0.008
  15. Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens. Gynecol Oncol. 2018 06; 149(3):570-574.
    View in: PubMed
    Score: 0.008
  16. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 2018 04; 37(17):2285-2301.
    View in: PubMed
    Score: 0.008
  17. Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer. Int J Gynecol Cancer. 2017 10; 27(8):1774-1782.
    View in: PubMed
    Score: 0.008
  18. Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. Cancer Prev Res (Phila). 2017 Apr; 10(4):255-266.
    View in: PubMed
    Score: 0.007
  19. Statin Use Significantly Improves Overall Survival in High-Grade Endometrial Cancer. Int J Gynecol Cancer. 2016 11; 26(9):1642-1649.
    View in: PubMed
    Score: 0.007
  20. Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov. 2016 12; 6(12):1342-1351.
    View in: PubMed
    Score: 0.007
  21. Nanoscale Coordination Polymers Codeliver Chemotherapeutics and siRNAs to Eradicate Tumors of Cisplatin-Resistant Ovarian Cancer. J Am Chem Soc. 2016 05 11; 138(18):6010-9.
    View in: PubMed
    Score: 0.007
  22. Can you ask? We just did! Assessing sexual function and concerns in patients presenting for initial gynecologic oncology consultation. Gynecol Oncol. 2015 Apr; 137(1):119-24.
    View in: PubMed
    Score: 0.006
  23. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest. 2014 Oct; 124(10):4614-28.
    View in: PubMed
    Score: 0.006
  24. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol. 2014 Oct 10; 32(29):3275-83.
    View in: PubMed
    Score: 0.006
  25. Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis. PLoS One. 2014; 9(8):e104521.
    View in: PubMed
    Score: 0.006
  26. Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group. Cancer. 2014 Feb 01; 120(3):344-51.
    View in: PubMed
    Score: 0.006
  27. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013 Feb; 14(2):134-40.
    View in: PubMed
    Score: 0.005
  28. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):22-7.
    View in: PubMed
    Score: 0.005
  29. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Dec; 127(3):506-10.
    View in: PubMed
    Score: 0.005
  30. The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy. Cancer. 2013 Jan 15; 119(2):325-31.
    View in: PubMed
    Score: 0.005
  31. Time-dependent transcriptional profiling links gene expression to mitogen-activated protein kinase kinase 4 (MKK4)-mediated suppression of omental metastatic colonization. Clin Exp Metastasis. 2012 Jun; 29(5):397-408.
    View in: PubMed
    Score: 0.005
  32. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2012 Jan; 119(1):61-7.
    View in: PubMed
    Score: 0.005
  33. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2012 Feb; 13(2):154-62.
    View in: PubMed
    Score: 0.005
  34. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Apr; 125(1):54-8.
    View in: PubMed
    Score: 0.005
  35. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011 Oct 30; 17(11):1498-503.
    View in: PubMed
    Score: 0.005
  36. Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2011 Nov; 123(2):182-6.
    View in: PubMed
    Score: 0.005
  37. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res. 2011 Jun 15; 17(12):4042-51.
    View in: PubMed
    Score: 0.005
  38. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2011 May 01; 121(2):264-8.
    View in: PubMed
    Score: 0.005
  39. Assessing gynecologic and breast cancer survivors' sexual health care needs. Cancer. 2011 Jun 15; 117(12):2643-51.
    View in: PubMed
    Score: 0.005
  40. The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma. Gynecol Oncol. 2011 Apr; 121(1):218-23.
    View in: PubMed
    Score: 0.005
  41. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res. 2011 Feb 01; 17(3):459-71.
    View in: PubMed
    Score: 0.005
  42. {beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol. 2009 Nov; 175(5):2184-96.
    View in: PubMed
    Score: 0.004
  43. Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues. Clin Cancer Res. 2009 May 01; 15(9):3196-204.
    View in: PubMed
    Score: 0.004
  44. Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. Cancer Treat Res. 2009; 149:335-51.
    View in: PubMed
    Score: 0.004
  45. c-Jun NH2-terminal kinase activating kinase 1/mitogen-activated protein kinase kinase 4-mediated inhibition of SKOV3ip.1 ovarian cancer metastasis involves growth arrest and p21 up-regulation. Cancer Res. 2008 Apr 01; 68(7):2166-75.
    View in: PubMed
    Score: 0.004
  46. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 2008 Apr 01; 68(7):2329-39.
    View in: PubMed
    Score: 0.004
  47. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer. 2007 Oct 01; 121(7):1463-72.
    View in: PubMed
    Score: 0.004
  48. Inherited plasminogen deficiency presenting as ligneous vaginitis: a case report with molecular correlation and review of the literature. Hum Pathol. 2007 Oct; 38(10):1569-75.
    View in: PubMed
    Score: 0.004
  49. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 2007 Feb 15; 67(4):1670-9.
    View in: PubMed
    Score: 0.004
  50. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1356-65.
    View in: PubMed
    Score: 0.003
  51. Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):1078-86.
    View in: PubMed
    Score: 0.003
  52. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res. 2004 Aug 15; 10(16):5546-53.
    View in: PubMed
    Score: 0.003
  53. Pathologic stage I-II endometrial carcinoma in the elderly: radiotherapy indications and outcome. Int J Radiat Oncol Biol Phys. 2004 Aug 01; 59(5):1432-8.
    View in: PubMed
    Score: 0.003
  54. Phase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies. Gynecol Oncol. 2004 Mar; 92(3):801-5.
    View in: PubMed
    Score: 0.003
  55. Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Nov 15; 57(4):1004-9.
    View in: PubMed
    Score: 0.003
  56. Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2003 Oct 01; 57(2):516-21.
    View in: PubMed
    Score: 0.003
  57. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Apr 01; 55(5):1272-6.
    View in: PubMed
    Score: 0.003
  58. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2002 Dec 01; 54(5):1388-96.
    View in: PubMed
    Score: 0.003
  59. Expression of cyclin-dependent kinase inhibitor p27/Kip1 and AP-1 coactivator p38/Jab1 correlates with differentiation of embryonal rhabdomyosarcoma. Jpn J Cancer Res. 2002 Sep; 93(9):1000-6.
    View in: PubMed
    Score: 0.003
  60. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2002 Apr 01; 52(5):1330-7.
    View in: PubMed
    Score: 0.003
  61. Outcome and management of pathological stage I endometrial carcinoma patients with involvement of the lower uterine segment. Gynecol Oncol. 2001 Dec; 83(3):513-7.
    View in: PubMed
    Score: 0.003
  62. An alpha-fetoprotein-producing hepatoid adenocarcinoma of the endometrium. Gynecol Oncol. 2001 Nov; 83(2):418-21.
    View in: PubMed
    Score: 0.003
  63. Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol. 2001 Sep; 82(3):456-63.
    View in: PubMed
    Score: 0.002
  64. Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2001 Aug 01; 50(5):1145-53.
    View in: PubMed
    Score: 0.002
  65. Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2001 Aug 01; 50(5):1154-60.
    View in: PubMed
    Score: 0.002
  66. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3) Nature. 1996 Dec 05; 384(6608):455-8.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.